AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23802640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid, 500 mg every eight hours, administered three times per day for 48 hours prior to bleaching sessions.
Number of subjects: 39
Study 23802640 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered three times per day for 48 hours prior to bleaching sessions.
Number of subjects: 39
Study 21416238 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planning (SRP)
Number of subjects: 28
Study 21416238 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + subgingival minocycline administration
Number of subjects: 28
Study 19258143 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL of 1% lidocaine
Number of subjects: 45
Study 19258143 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mL of 1% lidocaine
Number of subjects: 45
Study 19258143 — intervention group
Group type: COMPARATOR
Intervention: 1 mL of 1% lidocaine
Number of subjects: 45
Study 17445928 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) - 50 Gy/25 fx/5 weeks followed by 12 Gy/2 fx of high-dose-rate intra-lumenal brachytherapy (initially), later modified to 66 Gy/33 fx/6.5 weeks.
Number of subjects: 125
Study 17445928 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin chemo-radiotherapy (CRT) - identical radiotherapy with concurrent weekly cisplatin at 35 mg/m2 for 6-7 cycles.
Number of subjects: 125
Study 17445928 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (part of CRT)
Number of subjects: 125
Study 17445928 — intervention group
Group type: EXPERIMENTAL
Intervention: Late morbidity (ulcers)
Number of subjects: 125
Study 17445928 — intervention group
Group type: EXPERIMENTAL
Intervention: Late morbidity (strictures)
Number of subjects: 125
Study 15028129 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirilazad
Number of subjects: 3567
Study 15028129 — intervention group
Group type: COMPARATOR
Intervention: WFNS grading scale
Number of subjects: 3567
Study 12602080 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D3
Number of subjects: 1080
Study 10440800 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and B vaccine (two-dose schedule)
Number of subjects: 100
Study 10440800 — intervention group
Group type: COMPARATOR
Intervention: Monovalent vaccines (two-dose schedule)
Number of subjects: 100
Study 7761801 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Morse decoders with narrow-band noise at 80 signs/min
Number of subjects: 5
Study 7761801 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Morse decoders with narrow-band noise at 150 signs/min
Number of subjects: 5
Study 7761801 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Morse decoders with broad-band noise at 80 signs/min
Number of subjects: 5
Study 7761801 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Morse decoders with broad-band noise at 150 signs/min
Number of subjects: 5
Study 7761801 — intervention group
Group type: COMPARATOR
Intervention: Human recognition of Morse signs
Number of subjects: 5
Study 2117799 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3 as a prophylactic agent
Number of subjects: 0
Study 2117799 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3
Number of subjects: 0
Study 2117799 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3 in patients with ATN
Number of subjects: 0
Study 371743 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (600 mg i.m.)
Number of subjects: 238
Study 371743 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (1.1 g i.m.)
Number of subjects: 238
Study 371743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 30778649 — intervention group
Group type: EXPERIMENTAL
Intervention: Betrixaban for 35-42 days
Number of subjects: 703
Study 30778649 — intervention group
Group type: EXPERIMENTAL
Intervention: Betrixaban (full-dose stratum)
Number of subjects: 703
Study 30778649 — intervention group
Group type: EXPERIMENTAL
Intervention: Betrixaban (overall population)
Number of subjects: 703
Study 30778649 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin for 10±4 days
Number of subjects: 703
Study 30778649 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (full-dose stratum)
Number of subjects: 703
Study 28325823 — intervention group
Group type: EXPERIMENTAL
Intervention: Video consultations as add-on to clinic-based care
Number of subjects: 165
Study 28325823 — intervention group
Group type: COMPARATOR
Intervention: Standard care (clinic-based care)
Number of subjects: 165
Study 26200171 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 litres water per day + stress control and sleep hygiene
Number of subjects: 102
Study 26200171 — intervention group
Group type: COMPARATOR
Intervention: Stress control and sleep hygiene
Number of subjects: 102
Study 23720136 — intervention group
Group type: COMPARATOR
Intervention: Normal-fat breakfast
Number of subjects: 0
Study 23720136 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting conditions
Number of subjects: 0
Study 23720136 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat breakfast
Number of subjects: 0
Study 23720136 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-rich nutritional drink
Number of subjects: 0
Study 21999972 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-format behavioral self-management intervention for pain and insomnia
Number of subjects: 367
Study 20066887 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistive technology and home modification intervention
Number of subjects: 91
Study 20066887 — intervention group
Group type: COMPARATOR
Intervention: Standard community-available health care (Control)
Number of subjects: 91
Study 17910330 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine, 0.125 mg/kg, twice daily for 18 months
Number of subjects: 510
Study 17910330 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Number of subjects: 510
Study 17910330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 510
Study 14566153 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback
Number of subjects: 27
Study 14566153 — intervention group
Group type: COMPARATOR
Intervention: Placebo EMG biofeedback
Number of subjects: 27
Study 10971099 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 8877910 — intervention group
Group type: EXPERIMENTAL
Intervention: 13C-urea breath test (13C-UBT) with 38 mg 13C-urea
Number of subjects: 114
Study 8877910 — intervention group
Group type: EXPERIMENTAL
Intervention: 13C-urea breath test (13C-UBT)
Number of subjects: 114
Study 8877910 — intervention group
Group type: COMPARATOR
Intervention: Histology and rapid urease test (CLOtest)
Number of subjects: 114
Study 1737596 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 25
Study 1737596 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 25
Study 6378450 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymic humoral factor (THF)
Number of subjects: 20
Study 6378450 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 3741533 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous theophylline (0.48 g of theophylline-ethylenediamine, TE)
Number of subjects: 16
Study 3741533 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention enema (400 mg theophylline, 600 mg diprophylline, 600 mg proxyphylline, TDP)
Number of subjects: 16
Study 3741533 — intervention group
Group type: COMPARATOR
Intervention: Both TE and TDP
Number of subjects: 16
Study 29239764 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 9585
Study 29239764 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphonylureas
Number of subjects: 9585
Study 29239764 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 9585
Study 29239764 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipeptidyl peptidase 4 inhibitors (DPP‐4i)
Number of subjects: 9585
Study 29239764 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin and Saxagliptin
Number of subjects: 9585
Study 26894800 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 0
Study 25341118 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (VDZ)
Number of subjects: 0
Study 25341118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24294977 — intervention group
Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND)
Number of subjects: 0
Study 24294977 — intervention group
Group type: COMPARATOR
Intervention: Average Danish Diet (ADD)
Number of subjects: 0
Study 24294977 — intervention group
Group type: COMPARATOR
Intervention: Adjusted Average Danish Diet (ADD-m)
Number of subjects: 0
Study 24294977 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted New Nordic Diet (NND-m)
Number of subjects: 0
Study 20022733 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation during pregnancy and lactation
Number of subjects: 57
Study 20022733 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte DHA levels
Number of subjects: 57
Study 20022733 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte Arachidonic Acid (AA) levels
Number of subjects: 57
Study 20022733 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA/AA ratio
Number of subjects: 57
Study 20022733 — intervention group
Group type: EXPERIMENTAL
Intervention: Mead acid levels
Number of subjects: 57
Study 18004688 — intervention group
Group type: EXPERIMENTAL
Intervention: High GI and high GL (HH)
Number of subjects: 9
Study 18004688 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GI and low GL (LL)
Number of subjects: 9
Study 18004688 — intervention group
Group type: EXPERIMENTAL
Intervention: High GI and low GL (HL)
Number of subjects: 9
Study 16893753 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 85
Study 16893753 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 85
Study 16893753 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine
Number of subjects: 85
Study 16893753 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 85
Study 16893753 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (Control)
Number of subjects: 85
Study 14644697 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention group receiving a 5-year behavioral dietary and physical activity program
Number of subjects: 535
Study 14644697 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention group
Number of subjects: 535
Study 10706432 — intervention group
Group type: EXPERIMENTAL
Intervention: True information about performance (Condition A)
Number of subjects: 0
Study 10706432 — intervention group
Group type: COMPARATOR
Intervention: False information about performance (Condition B)
Number of subjects: 0
Study 10706432 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning effect observed in both conditions
Number of subjects: 0
Study 9037359 — intervention group
Group type: EXPERIMENTAL
Intervention: PEB (cisplatin, etoposide, bleomycin)
Number of subjects: 54
Study 9037359 — intervention group
Group type: COMPARATOR
Intervention: CEB (carboplatin, etoposide, bleomycin)
Number of subjects: 54
Study 9037359 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative events
Number of subjects: 54
Study 1909748 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitrate therapy
Number of subjects: 0
Study 1909748 — intervention group
Group type: COMPARATOR
Intervention: Oral nitrate therapy
Number of subjects: 0
Study 6397454 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin together with low dose dopamine infusion
Number of subjects: 15
Study 6397454 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin alone
Number of subjects: 15
Study 31619300 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical site infections (SSIs)
Number of subjects: 4556
Study 31619300 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical site infections (non-SSIs)
Number of subjects: 4556
Study 31619300 — intervention group
Group type: EXPERIMENTAL
Intervention: Private insurance
Number of subjects: 4556
Study 31619300 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU admission
Number of subjects: 4556
Study 31619300 — intervention group
Group type: COMPARATOR
Intervention: NHS England simulation
Number of subjects: 4556
Study 29560795 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse assessment of PICC site using a seven-item assessment tool
Number of subjects: 73
Study 29560795 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient assessment of PICC site using a seven-item assessment tool
Number of subjects: 73
Study 26753792 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone treatment
Number of subjects: 173
Study 26753792 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patients
Number of subjects: 173
Study 26753792 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with pain
Number of subjects: 173
Study 26753792 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with high or very high nicotine dependence
Number of subjects: 173
Study 26753792 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients at suicidal risk
Number of subjects: 173
Study 24524214 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-week online insomnia treatment programme, Sleep Healthy Using The internet (SHUTi)
Number of subjects: 1600
Study 24524214 — intervention group
Group type: COMPARATOR
Intervention: Online attention-matched control group (HealthWatch)
Number of subjects: 1600
Study 23018304 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6% hyaluronic acid/4.0% chondroitin sulfate
Number of subjects: 39
Study 23018304 — intervention group
Group type: COMPARATOR
Intervention: 2.0% hydroxypropylmethylcellulose
Number of subjects: 39
Study 20231896 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sodium stibogluconate (SSG) 20mg/kg/day for ten doses
Number of subjects: 56
Study 20231896 — intervention group
Group type: COMPARATOR
Intervention: Localized ThermoMed (TM) device heat treatment (applied at 50 degrees C for 30 seconds) in one session
Number of subjects: 56
Study 17398320 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 IU/ml low-molecular-weight heparin (LMWH) and 200 mug/ml 5-Fluorouracil (5FU) added to the perioperative infusion fluid
Number of subjects: 641
Study 17398320 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no adjuvant therapy)
Number of subjects: 641
Study 15542577 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle exercise (50% of peak oxygen uptake)
Number of subjects: 21
Study 15542577 — intervention group
Group type: COMPARATOR
Intervention: Control (seated rest)
Number of subjects: 21
Study 12188401 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (Zocor), dosage 10 mg
Number of subjects: 48
Study 12188401 — intervention group
Group type: COMPARATOR
Intervention: Generic simvastatin (Unison), dosage 10 mg
Number of subjects: 48
Study 11938791 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 80
Study 11938791 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 80
Study 11938791 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (rectum or vagina)
Number of subjects: 80
Study 8887188 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) therapy after GnRH-a administration
Number of subjects: 23
Study 8887188 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (GnRH-a plus OC 'addback') for six months
Number of subjects: 23
Study 8887188 — intervention group
Group type: COMPARATOR
Intervention: GnRH-a (depot every 28 days) for six months
Number of subjects: 23
Study 1324109 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive verbalizations (VP)
Number of subjects: 46
Study 1324109 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative verbalizations (VN)
Number of subjects: 46
Study 1324109 — intervention group
Group type: COMPARATOR
Intervention: Control group (T)
Number of subjects: 46
Study 6326562 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (15 g/day)
Number of subjects: 14
Study 6326562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30647402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal nerve block with ropivacaine (group A)
Number of subjects: 100
Study 30302335 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 µg
Number of subjects: 0
Study 30302335 — intervention group
Group type: COMPARATOR
Intervention: Twice daily budesonide/formoterol (BUD/FOR) 400/12 μg
Number of subjects: 0
Study 27717374 — intervention group
Group type: EXPERIMENTAL
Intervention: Minding the Baby® (MTB) programme
Number of subjects: 200
Study 27717374 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 200
Study 24962856 — intervention group
Group type: EXPERIMENTAL
Intervention: ART (Augmented Reality Telementoring)
Number of subjects: 19
Study 24962856 — intervention group
Group type: COMPARATOR
Intervention: Traditional mentoring
Number of subjects: 19
Study 21159473 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 1.5 mg
Number of subjects: 0
Study 21159473 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 20 mg
Number of subjects: 0
Study 21159473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20137360 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.15 mg/kg; maximum 20 mg)
Number of subjects: 106
Study 20137360 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 106
Study 18721708 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof SN60AT IOL
Number of subjects: 36
Study 18721708 — intervention group
Group type: COMPARATOR
Intervention: AF‐1 YA‐60BB IOL
Number of subjects: 36
Study 16512103 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt containing Bifidobacterium DN-173 010 (200 g once daily for 2 weeks)
Number of subjects: 21
Study 16512103 — intervention group
Group type: COMPARATOR
Intervention: Control yogurt without viable bacteria (200 g once daily for 2 weeks)
Number of subjects: 21
Study 12466782 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg)
Number of subjects: 90
Study 12466782 — intervention group
Group type: COMPARATOR
Intervention: Hyperinsulinemic euglycemic clamping
Number of subjects: 90
Study 12466782 — intervention group
Group type: COMPARATOR
Intervention: Comparison of image quality
Number of subjects: 90
Study 9951429 — intervention group
Group type: EXPERIMENTAL
Intervention: R-568 (calcium receptor agonist)
Number of subjects: 18
Study 9951429 — intervention group
Group type: EXPERIMENTAL
Intervention: R-568 (80 to 160 mg doses)
Number of subjects: 18
Study 9951429 — intervention group
Group type: EXPERIMENTAL
Intervention: R-568
Number of subjects: 18
Study 7844610 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethyldithiocarbamate (DDTC) 1.6 g/m2 over 4 hours, administered intravenously every 4 weeks for six cycles
Number of subjects: 221
Study 7844610 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PB), administered intravenously every 4 weeks for six cycles
Number of subjects: 221
Study 7844610 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethyldithiocarbamate (DDTC)
Number of subjects: 221
Study 7844610 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PB)
Number of subjects: 221
Study 2189954 — intervention group
Group type: EXPERIMENTAL
Intervention: MVAC chemotherapy
Number of subjects: 110
Study 2189954 — intervention group
Group type: COMPARATOR
Intervention: CISCA chemotherapy
Number of subjects: 110
Study 446321 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional treatment with piracetam (Normabrain, Nootrop, 9 g/d intravenously)
Number of subjects: 36
Study 446321 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 36
Study 30535355 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OXT)
Number of subjects: 187
Study 30535355 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 187
Study 30773864 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 84
Study 30773864 — intervention group
Group type: COMPARATOR
Intervention: Acupoint catgut embedding
Number of subjects: 84
Study 30773864 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (EA and catgut embedding)
Number of subjects: 84
Study 29117276 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 27564
Study 29117276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27564
Study 26031193 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HTP (100 mg orally)
Number of subjects: 30
Study 26031193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23609398 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol (2.5 mg) + midazolam (7.5 mg)
Number of subjects: 100
Study 23609398 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine (10 mg)
Number of subjects: 100
Study 23609398 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol (2.5 mg) + promethazine (25 mg)
Number of subjects: 100
Study 23609398 — intervention group
Group type: EXPERIMENTAL
Intervention: ziprasidone (10 mg)
Number of subjects: 100
Study 21893650 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycled therapy (tobramycin inhalation solution 300 mg twice a day for 28 days + oral ciprofloxacin 15-20 mg/kg twice a day for 14 days every quarter)
Number of subjects: 304
Study 21893650 — intervention group
Group type: COMPARATOR
Intervention: Culture-based therapy (same treatments only during quarters with positive P aeruginosa cultures)
Number of subjects: 304
Study 21893650 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (15-20 mg/kg twice a day for 14 days every quarter)
Number of subjects: 304
Study 21893650 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral placebo for 14 days every quarter)
Number of subjects: 304
Study 21893650 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycled therapy
Number of subjects: 304
Study 21893650 — intervention group
Group type: COMPARATOR
Intervention: Culture-based therapy
Number of subjects: 304
Study 21893650 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 304
Study 21893650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304